Offer Request Form

Order list is empty

Measuring Biological Drug Levels and the Relevance of Trough Levels, Including Anti-Drug Antibodies: Biologics as Personalized-Precision Medicines

Measuring Biological Drug Levels and the Relevance of Trough Levels, Including Anti-Drug Antibodies: Biologics as Personalized-Precision Medicines

Prof. Haluk Ataoglu MD, PhD, CEO
Matriks Biotechnology Co.

28 January 2025

Introduction

Biological drugs—such as monoclonal antibodies—have transformed the treatment landscape for various autoimmune diseases, cancers, and other chronic conditions. Despite their remarkable therapeutic potential, these agents are also associated with high costs and variable patient responses. Consequently, measuring biological drug levels (particularly trough levels) and detecting anti-drug antibodies (ADAs) have become central strategies for optimizing therapy, reducing adverse effects, and managing healthcare costs.

This article provides an overview of why and how monitoring trough levels and ADAs can enhance personalized medicine, ensuring that patients achieve optimal benefit from biologic therapies.

To read the full publication please click here